Supportive care
No publications
General
Myeloma escape from immunity: an “inside” job. Rapoport AP. Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490. Antibody based immunotherapy for multiple myeloma: It’s about time. Sher T et al, Leuk Lymphoma. 2015 Sep 16:1-17. [Epub ahead of print]. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Sep 4. [Epub ahead of…
Complications of myeloma and its treatments
Early Surgical Occipito-Cervical Stabilization for Plasma Cell Neoplasms at the Cranio-Cervical Junction – Systematic Review and Proposal of a Treatment Algorithm. Ahmadi SA et al. Spine J. 2015 Sep 24. pii: S1529-9430(15)01442-4. doi: 10.1016/j.spinee.2015.09.032. [Epub ahead of print]. Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myelomawith concomitant thoracic fractures. Butler JS et…
Current treatments
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL et al. J Clin Apher. 2015 Sep 5. doi: 10.1002/jca.21421. [Epub ahead of print]. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Jagirdar N et al. Transfusion. 2015 Sep 2.…
IMWG Revised International Staging System (R-ISS) for Multiple Myeloma
The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
Supportive care
Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P et al. Eur J Haematol. 2015 Aug 6. doi: 10.1111/ejh.12644. [Epub ahead of print].
General
Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents. Cook G. Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.175. [Epub ahead of print]. IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature. Mitra S et al. Indian J Hematol Blood Transfus. 2015 Dec;31(4):472-9. doi: 10.1007/s12288-014-0454-5.…
Complications of myeloma and its treatments
Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy. Gu ZH et al. Int J Clin Exp Med. 2015 Jun 15;8(6):10105-10108. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Vincent L et al. Blood Cancer J. 2015 Aug 21;5:e341. doi: 10.1038/bcj.2015.48. Hematopoietic cell transplantation in patients with medication-related osteonecrosis of the jaws. Mawardi…
Current treatments
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.60.2466. [Epub ahead of print]. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myelomapatients aged 65 years or older: a retrospective single Institutional analysis. Minoia C et al. Bone Marrow Transplant. 2015 Aug…
NICE issues new draft guidelines for end of life care
The National Institute for Health and Care Excellence (NICE) has issued draft guidelines for consultation to improve the care of adults during the last few days of life. The guidelines are meant to replace the Liverpool Care Pathway which were phased out in 2014. Key recommendations highlight the importance of communication and shared decision-making involving…